Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2012
Radiation dosimetry and biodistribution of the TSPO ligand 11C-DPA-713 in humans.
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- Radiosynthesis and characterization of [European journal of nuclear medicine and molecular imaging · 2021Article
- Recent developments on PET radiotracers for TSPO and their applications in neuroimaging.Acta pharmaceutica Sinica. B · 2021Review
- Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- VDAC1 and the TSPO: Expression, Interactions, and Associated Functions in Health and Disease States.International journal of molecular sciences · 2019Review
- Microglial activation mediates chronic mild stress-induced depressive- and anxiety-like behavior in adult rats.Journal of neuroinflammation · 2018Article
- Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases.Nuclear medicine and molecular imaging · 2017Review
- Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
- In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV.Journal of neurovirology · 2014Article
- Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis.Arthritis research & therapy · 2014Article
- Sex differences in translocator protein 18 kDa (TSPO) in the heart: implications for imaging myocardial inflammation.Journal of cardiovascular translational research · 2014Article
- Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.Translational psychiatry · 2014Review
- Biomarker and more: can translocator protein 18 kDa predict recovery from brain injury and myocarditis?Biomarkers in medicine · 2014Article
- Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713.The Journal of infectious diseases · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
unlabelledWhole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET ligand for the assessment of translocator protein.
methodsSix healthy control subjects, 3 men and 3 women, underwent whole-body dynamic PET scans after bolus injection of (11)C-DPA-713. Subjects were scanned from head to mid thigh with 7 passes performed, with a total PET acquisition of approximately 100 min. Time-activity curves were generated in organs with visible tracer uptake, and tissue residence times were calculated. Whole-body dosimetry was calculated using OLINDA 1.1 software, assuming no voiding.
resultsThe absorbed dose is highest in the lungs, spleen, kidney, and pancreas. The lungs were determined to be the dose-limiting organ, with an average absorbed dose of 2.01 × 10(-2) mSv/MBq (7.43 × 10(-2) rem/mCi). On the basis of exposure limits outlined in the U.S. Food and Drug Administration Code of Federal Regulations (21CFR361.1), the single-dose limit for (11)C-DPA-713 radiotracer injection is 2,487.6 MBq (67.3 mCi).
conclusion(11)C-DPA-713 has an uptake pattern that is consistent with the biodistribution of translocator protein and yields a dose burden that is comparable to that of other (11)C-labeled PET tracers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.